Ajanta Pharmaceuticals cash flow

Latest FY26

Cash from operations: ₹529cr−54.3% on FY25
Capital spending: ₹365cr+14.9% on FY25
Free cash flow: ₹164cr−80.5% on FY25
Cash from financing: −₹168cr−₹733 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	173	144	135	131
	—	4.1	0.6	−3.5	5.4
	—	16.1	20.7	7.2	5.8
	—	−60.3	−59.1	−38.1	−17.6
	—	87.4	12.5	−13.7	21.1
	—	1.5	3.9	5.5	0.2
	—	−58.1	−10.3	−9.4	−14.1
	—	−0.3	−0.3	−0.3	−0.3
	—	−31.0	−74.5	−12.3	−22.4
	—	−591	80.5	−179	−10.6
	—	0.0	0.0	17.4	32.3
	—	0.0	0.0	1.7	1.0
	—	−159	25.3	−40.9	6.9
	—	0.0	0.0	−1.0	0.3
	—	90.8	−8.5	40.9	96.9
	—	0.0	0.0	19.5	0.4
	—	0.0	0.0	0.7	−0.1
	—	59.3	116	36.6	−44.0
	—	−22.4	40.5	1.2	0.9
	—	0.0	0.0	15.4	4.8
Cash from operating activities
	1,493	1,378	1,189	1,114	745
	—	−489	291	−16.7	198
	—	888	1,480	1,097	943
	—	359	323	312	151
	—	529	1,157	785	792
Cash from investing activities
	—	365	318	152	174
	—	5.4	1.1	13.4	0.7
	—	2,660	2,761	2,080	1,667
	—	2,549	2,663	2,257	1,276
	—	3.3	6.3	0.0	0.0
	—	45.4	44.1	27.0	0.5
	—	−0.4	0.2	−0.2	4.4
	—	−429	−377	65.4	−560
Cash from financing activities
	—	0.0	0.0	0.0	0.0
	—	0.0	353	389	1.4
	—	209	1.1	0.1	0.0
	—	0.0	0.0	0.0	0.5
	—	14.8	14.9	16.2	14.3
	—	12.8	17.3	3.5	2.3
	—	350	349	642	89.7
	—	0.0	0.0	0.0	0.3
	—	−168	−733	−1,051	−108
	—	−67.7	47.3	−201	124
	—	−4.2	−1.7	0.3	−0.8
	—	−71.9	45.6	−200	123
	—	—	—	129	330
Reference items
	1,467	1,395	1,260	1,172	783
	25.4%	25.6%	27.1%	27.9%	20.9%
	164	164	839	633	617
	—	361	823	629	—
	₹13.09	₹13.09	₹66.96	₹50.47	₹49.25
	264.39×	—	—	—	—
	—	0.50×	1.26×	0.96×	1.35×
	—	359	323	312	151
	—	12.8	17.3	3.5	2.3

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AJANTPHARM₹3,459.80

Ajanta Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersALKEM IPCALAB TORNTPHARM ABBOTINDIA ANTHEM GLAXO MEDANTA GLENMARKMcap ₹43,369 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	130.8	135.4	144.1	173.1	—
+ Impairment Loss / (Reversal)	5.4	-3.5	0.6	4.1	—
+ Finance Costs	5.8	7.2	20.7	16.1	—
+ Interest Income	-17.6	-38.1	-59.1	-60.3	—
+ Fair Value (Gains) / Losses	21.1	-13.7	12.5	87.4	—
+ Share-based Payments	0.2	5.5	3.9	1.5	—
+ Unrealised FX (Gain) / Loss	-14.1	-9.4	-10.3	-58.1	—
+ Other Non-cash Items	-0.3	-0.3	-0.3	-0.3	—
Changes in Working Capital
+ Inventories	-22.4	-12.3	-74.5	-31.0	—
+ Trade Receivables — Current	-10.6	-178.9	80.5	-590.8	—
+ Other Financial Assets — Current	32.3	17.4	0.0	0.0	—
+ Other Financial Assets — Non-current	1.0	1.7	0.0	0.0	—
+ Other Current Assets	6.9	-40.9	25.3	-158.8	—
+ Other Non-current Assets	0.3	-1.0	0.0	0.0	—
+ Trade Payables — Current	96.9	40.9	-8.5	90.8	—
+ Other Financial Liabilities — Current	0.4	19.5	0.0	0.0	—
+ Other Financial Liabilities — Non-current	-0.1	0.7	0.0	0.0	—
+ Other Current Liabilities	-44.0	36.6	115.6	59.3	—
+ Provisions — Current	0.9	1.2	40.5	-22.4	—
+ Provisions — Non-current	4.8	15.4	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	745.3	1,113.9	1,189.2	1,377.7	1,493.3
+ Total Adjustments (incl. Working Capital)	197.8	-16.7	291.0	-489.5	—
Cash from Operations (pre-tax)	943.1	1,097.2	1,480.2	888.2	—
+ Income Taxes Paid	151.3	312.1	323.0	359.0	—
Cash from Operating Activities	791.8	785.1	1,157.2	529.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	174.5	152.4	317.9	365.2	—
+ Disp of Fixed Assets	0.7	13.4	1.1	5.4	—
+ Purchase of Investments (Equity / Debt)	1,666.9	2,079.8	2,761.2	2,660.0	—
+ Sale of Investments (Equity / Debt)	1,276.2	2,257.4	2,663.5	2,549.1	—
+ Investment in Partnership Firms / LLPs	0.0	0.0	6.3	3.3	—
+ Interest Received — Investing	0.5	27.0	44.1	45.4	—
+ Other Inflows / (Outflows) — Investing	4.4	-0.2	0.2	-0.4	—
Cash from Investing Activities	-559.6	65.4	-376.5	-428.9	—
Cash from Financing Activities
+ Proceeds from Other Equity Instruments	0.0	0.0	0.0	0.0	—
+ Buyback / Redemption of Own Shares	1.4	389.2	353.0	0.0	—
+ Proceeds from Borrowings	0.0	0.1	1.1	209.4	—
+ Repayment of Borrowings	0.5	0.0	0.0	0.0	—
+ Payment of Lease Liabilities	14.3	16.2	14.9	14.8	—
+ Interest Paid	2.3	3.5	17.3	12.8	—
+ Dividends Paid	89.7	642.2	349.4	349.7	—
+ Other Inflows / (Outflows) — Financing	0.3	0.0	0.0	0.0	—
Cash from Financing Activities	-107.9	-1,051.1	-733.4	-167.9	—
Net Changes in Cash (pre-FX)	124.3	-200.6	47.3	-67.7	—
+ Effect of FX Rate Changes on Cash	-0.8	0.3	-1.7	-4.2	—
Net Changes in Cash	123.5	-200.3	45.6	-71.9	—
Closing Cash	329.8	129.5	—	—	—
Reference Items
EBITDA	783.3	1,171.9	1,259.5	1,394.8	1,467.1
EBITDA Margin %	20.93	27.85	27.10	25.58	25.40
Free Cash Flow (CFO − Capex)	617.3	632.7	839.3	164.0	164.0
Free Cash Flow to Equity	—	629.2	823.1	360.6	—
Free Cash Flow per Basic Share	49.25	50.47	66.96	13.09	13.09
Price to Free Cash Flow	—	—	—	—	264.39
Cash Flow to Net Income	1.35	0.96	1.26	0.50	—
Cash Paid for Taxes	151.3	312.1	323.0	359.0	—
Cash Paid for Interest	2.3	3.5	17.3	12.8	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.